Hahn NM, Powles T, Massard C, et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC). J Clin Oncol. 2017;35 (suppl; abstr 4525).
AI-biomarker voor respons op atezolizumab-bevacizumab bij HCC
jan 2024 | Maag-darm-leveroncologie